ABSTRACT: Myotonic dystrophy type 1 (DM1) is caused by an expanded CUG repeat (CUG exp ) that sequesters muscleblind-like 1 protein (MBNL1), a protein that regulates alternative splicing. CUG exp RNA is a validated drug target for this currently untreatable disease. Herein, we develop a bioactive small molecule (1) that targets CUG exp RNA and is able to inhibit the CUG exp ·MBNL1 interaction in cells that model DM1. The core of this small molecule is based on ligand 2, which was previously reported to be active in an in vitro assay. A polyamine-derivative side chain was conjugated to this core to make it aqueous-soluble and cell-penetrable. In a DM1 cell model this conjugate was found to disperse CUG exp ribonuclear foci, release MBNL1, and partially reverse the mis-splicing of the insulin receptor pre-mRNA. Direct evidence for ribonuclear foci dispersion by this ligand was obtained in a live DM1 cell model using time-lapse confocal microscopy.
* S Supporting Information
ABSTRACT: Myotonic dystrophy type 1 (DM1) is caused by an expanded CUG repeat (CUG exp ) that sequesters muscleblind-like 1 protein (MBNL1), a protein that regulates alternative splicing. CUG exp RNA is a validated drug target for this currently untreatable disease. Herein, we develop a bioactive small molecule (1) that targets CUG exp RNA and is able to inhibit the CUG exp ·MBNL1 interaction in cells that model DM1. The core of this small molecule is based on ligand 2, which was previously reported to be active in an in vitro assay. A polyamine-derivative side chain was conjugated to this core to make it aqueous-soluble and cell-penetrable. In a DM1 cell model this conjugate was found to disperse CUG exp ribonuclear foci, release MBNL1, and partially reverse the mis-splicing of the insulin receptor pre-mRNA. Direct evidence for ribonuclear foci dispersion by this ligand was obtained in a live DM1 cell model using time-lapse confocal microscopy.
RNA is an important, yet underutilized, drug target. To date, the most common RNA drug targets have been ribosomal RNA and HIV RNA. 1−3 With recent structural and functional discoveries, non-coding RNA is gradually becoming an attractive drug target 4−6 and much is now known about designing ligands to interact with RNA. 7−9 Myotonic dystrophy (dystrophia myotonica, DM) is among the pathologies where RNA stands as the most appropriate target for drug discovery. 10 DM is the most common adult muscular dystrophy with a prevalence of 1:8,000 to 1:20,000 worldwide. 11 Currently there is no treatment for DM, only palliative therapy. 12 Myotonic dystrophy type 1 (DM1), originates from the progressive expansion of CTG repeats in the 3′-untranslated region of the DMPK gene. Thus, expanded CUG repeat transcripts (CUG exp ) are the known causative agent of DM1. 13, 14 The CUG exp RNA manifests its toxicity through a gain-of-function mechanism involving the sequestration of all three paralogs of human MBNL including MBNL1, a key regulatory protein of alternative splicing. 15−17 The MBNL1·CUG exp aggregate forms ribonuclear foci, a hallmark of DM1 cells. 18 In a mouse model of DM1, a morpholino antisense oligonucleotide (ASO), 19 2′-O-(2-methoxyethyl) ASO, 20 and D-amino acid hexapeptide, each targeting CUG exp , rescued the mis-splicing and reversed the phenotype. 21 These studies validated CUG exp as a drug target and greatly increased interest in finding small molecules that function similarly. Pentamidine, 22 benzo[g]quinolone-based heterocycles, 23 a Hoechst derivative (H1), 24 a modularly assembled Hoechst 33258, 25, 26 and ligand 2, reported by our laboratory, 27 are examples of bioactive CUG repeat binders at various stages of development as potential therapeutic agents for DM1.
Our previously reported approach, which led to ligand 2 as a binder of CUG, was based on the notion that selectivity was paramount and could be achieved by rational design focusing on recognition of the UU mismatch in double-stranded CUG exp . 26 We found that the triaminotriazine ring (recognition unit) has a key role in the inhibition of (CUG) 12 ·MBNL1 interaction as several acridine derivatives that lacked this unit showed no inhibition potency in an in vitro assay (Arambula, J. Ph.D. Thesis, University of Illinois, 2008). Although 2 proved to be among the most selective and effective inhibitors of the (CUG) 12 ·MBNL1 interaction, despite its in vitro activity it was not active in a cellular model of DM1. Its drugability was limited both because of its low water solubility and its inability to penetrate the cellular membrane. Herein we report further development of this small molecule into an active ligand in vivo through its conjugation to a cationic polyamine and the first observation using timelapse confocal microscopy of foci dispersion in live cells that model DM1.
■ RESULTS AND DISCUSSION
Ligand 1 ( Figure 1 ) is a conjugate of the previously reported in vitro active ligand 2 ( Figure 1 ) and N-[3-({3-[(3-aminopropyl)-amino]propyl}amino)propyl] acetamide side chain. The synthesis scheme of 1 is shown in Supplementary Figure 3 . The choice of the side chain was guided by four objectives: (1) increasing its aqueous solubility, (2) increasing its affinity to RNA through electrostatic interactions with the phosphate backbone, 28 (3) not adding to its cytotoxicity, and most importantly, (4) making it cell-as well as nucleus-penetrable. In fact, polyamine compounds are essential for cell growth and are easily transported across cellular membranes via the polyamine transporting system (PTS). 29 We were encouraged by the fact that previously reported acridinepolyamine conjugates were recognized by the PTS for cellular uptake. 30, 31 These conjugates also exhibited increased activity for nucleic acids. 32 Stability of Model CUG exp and Effect of Ligand 1. The binding of 1 to a model of CUG exp was studied by UV melting experiments. Thus, a thermal denaturation study of (CUG) 12 , a validated model of CUG exp , 33 was carried out in the presence of 1 and 3 equiv of ligand 1 ( Figure 2a) ; simple monophasic melting curves with a ΔT m of 2.5 and 5.5°C were observed, respectively ( Figure 2b and Supplementary Figure 10 ). This finding indicates binding of 1 to (CUG) 12 and stabilization of the double-stranded (ds) (CUG) 12 hairpin. The latter finding is important because it has been proposed that MBNL1 displays a preference for singlestranded (ss) RNA. 34, 35 If this model is correct, any ligand that stabilizes the ds form of CUG exp may prove to be a more effective inhibitor of the (CUG) 12 ·MBNL1 interaction. Thus, the observed stabilization of the ds form of (CUG) 12 was an encouraging result, although not sufficient to ensure selective and effective inhibition of (CUG) 12 ·MBNL1 interaction.
Inhibition of (CUG) 12 ·MBNL1 Interaction by 1. To our knowledge, SPR has not previously been used to characterize the MBNL1·CUG interaction or its inhibition by small molecules. 23, 36 Because the technique is particularly well suited for quantifying the binding of proteins to a target on the SPR chip, we developed a simple SPR-based method to directly measure MBNL1 complexation of (CUG) 12 in real time under equilibrium conditions and in a label-free format. Further, we were able to quantify the inhibition potency of 1 and its selectivity. The selectivity was assessed by performing the assay in the presence of a large excess of competitor tRNA.
Thus, biotinylated (CUG) 12 was immobilized on a streptavidincoated SPR sensor chip and incubated with different concentrations of 1 to reach a steady state response (response units, RU, see Figure 3a) over 150 s. The response to the binding of 1 was negligible in comparison to protein binding so the direct contribution of 1 could be ignored. Successive injections of a 0.65 μM solution of MBNL1 containing the same concentration of 1 as in the preincubation led to varying responses depending on the concentration of 1. Because the SPR signal directly reflects the binding of MBNL1 to the biotinylated (CUG) 12 , the differences in the response curves are a direct result of inhibition by 1.
The curves recorded in the presence and absence of 580 μM yeast tRNA were identical, indicating selective inhibition by 1. All of the data shown herein were from runs in the presence of tRNA. The maximum RU at 150 s was recorded for each concentration of 1 and converted to the fraction of (CUG) 12 bound by MBNL1, all values normalized to that measured in the absence of 1. Fitting the data points in the plot of % (CUG) 12 bound by MBNL1 versus increasing concentrations of 1 ( Figure 3b ) gave an apparent IC 50 value of 15 ± 2 μM.
These in vitro experiments demonstrate that 1 binds to (CUG) 12 , stabilizing the hairpin structure and inhibiting (CUG) 12 ·MBNL1 interaction selectively. It is noteworthy that all of the in vitro experiments above were carried out with (CUG) 12 in 1X PBS buffer. This particular buffer was chosen because it is the closest of common buffers to physiological conditions. It is also a more challenging buffer for small molecule inhibitors because it increases the (CUG) 12 ·MBNL1 stability, as we obtained a K D value of 5.2 ± 2.5 nM for (CUG) 12 ·MBNL1 interaction in this buffer by SPR technique whereas using EMSA we and others had reported K D values of 26 and 170 nM, respectively. 27,33 Bioactivity in DM1 Cell Model. It is a characteristic of DM1 cells that MBNL1 aggregates with CUG exp in nuclear foci. 37 To visualize the effect of 1 on these ribonuclear foci, we used confocal microscopy. This was accomplished using a model for a DM1 cell. Thus, HeLa cells were transfected with two plasmids, truncated DMPK-CUG 960 and GFP-MBNL1. 38 As a negative control, HeLa cells were transfected with truncated DMPK-CUG 0 (i.e., no CUG repeat) and GFP-MBNL1 plasmids. 38 To detect (CUG) 960 foci, Cy3-(CAG) 10 was used as a fluorescence in situ hybridization (FISH) probe. TO-PRO-3 was used to stain the nucleus; this particular dye was chosen because it has no overlap with the other three fluorophores in our system, i.e., the acridine ring of 1, the GFP of GFP-MBNL1, and the Cy3 of the FISH probe. By taking advantage of the acridine fluorescence, the penetration of 1 to the cytoplasm as well as nucleus is tracked in the ligand-treated cells.
Representative images from the confocal microscopy are shown in Figure 4 . The negative control cells lacking the (CUG) 960 sequence showed no foci but rather MBNL1 dispersed throughout the nucleus (Figure 4a, row 1) . However, co-localized MBNL1 and (CUG) 960 foci were observed in the DM1 cell model (Figure 4a , row 2). Thus, in the untreated DM1 cells the merged GFP-MBNL1 (green fluorescence) and Cy3-(CAG) 10 (red fluorescence) images showed yellow spots that correspond to MBNL1 and (CUG) 960 co-localization in nuclear foci (last column Figure 4 ). Likewise, incubation of the DM1 cell model with a negative control compound, 50 μM spermine, for 48 h had no effect on the foci (Figure 4a, row 3) . However, incubation with 1, at 50 and 75 μM, caused almost complete disappearance of the (CUG) 960 foci and dispersion of the MBNL1 fluorescence (Figure 4a , rows 4 and 5, respectively). The foci disruption is observed as a disappearance, rather than dispersion, of the FISH probe, because it is an exogenous antisense nucleic acid probe only visible when concentrated by a highly localized concentration of CUG exp RNA. 39 Cells were classified as having or not having foci. The fraction of cells with (CUG) 960 foci was reduced by ca. 86% with 1 at 75 μM with a two-tailed p-value of 0.004 (Figure 4b ). Similar responses are seen at 50 and 100 μM ligand.
Improvement of Pre-mRNA Mis-splicing by 1. After confirming that 1 disperses the MBNL1 foci, we sought to study the alternative splicing as a downstream measure of recovered MBNL1 regulatory activity. MBNL1 is known to be a key regulatory protein in alternative splicing and affecting many premRNAs, including the insulin receptor (IR). 40 The mis-splicing of IR in DM1 cells occurs with a predominance of isoform A (with exon 11 exclusion) relative to isoform B (with exon 11 inclusion). 41 As described above, truncated DMPK mRNAs containing (CUG) 960 or no CUG repeats were expressed in HeLa cells to serve as our DM1 cell model and negative control cell, respectively. These cells were co-transfected with an IR mini-gene to study the regulation of splicing of IR by measuring the relative amounts of its two isoforms. Looking at the transcripts in the DM1 cell model showed mis-splicing of IR with 35 ± 2% isoform B (IR-B), whereas 57 ± 1% of IR-B, measured in the negative control cell, was considered the baseline exon inclusion. Treatment of the DM1 cell model with a negative control compound, 50 μM spermine, had no effect on the IR mis-splicing (Supplementary Figure 9) . The splicing assay was repeated with different concentrations of 1 to see if it was capable of rescuing the mis-splicing of IR, i.e., increasing the fraction of IR-B (Figure 5a) . 42 Thus, the DM1 model cells were treated with 1 at 50, 75, or 150 μM for 48 h. A rescue of 40% for the IR splicing defect was observed at 75 μM with 45 ± 1% IR-B measured; two-tailed p-values of 0.002 (Figure 5b ). Similar responses are seen at 50 and 150 μM ligand. A more quantitative approach would be needed to demonstrate a dose response. It is noteworthy that cytotoxicity of 1 was evaluated by sulforhodamine B assay and less than 10% HeLa cell death was observed at the highest tested concentration (100 μM) after 24 h (Supplementary Figure 11) . MBNL1 Foci Dispersion in Live Cells by 1. Although the reduction in the foci-containing fixed cells was statistically significant, that experiment represents an indirect measurement of the foci dispersion, because with fixed-cell microscopy, we are not following the same cell directly over time to observe the dispersion of ribonuclear foci upon addition of 1. Thus, to further confirm our observation, we sought to investigate the effect of 1 in a live cell, by time-lapse confocal microscopy.
To monitor drug uptake and foci dispersion in real time, model DM1 cells were incubated with 1 at 75 μM, and individual live cells were monitored by confocal microscopy at several time points. The first observation at time point t = 0 was made immediately before addition of 1 and MBNL1 nuclear foci were clearly present (Figure 6a , t = 0). We found it necessary to use a Petri dish with an imprinted 500 μm grid to relocate the cell following the incubation interval.
The ability to monitor the location of 1 was made possible by the inherent fluorescence of the acridine unit. Over time, 1 penetrated the cellular and nuclear membrane, and the MBNL1 foci gradually dispersed over the entire nucleus (Figure 6a , t = 2, 4, and 7 h). The intensity of a representative MBNL1 focus (the most intense focus) at these four time points shows this dispersion (Figure 6b) . A negative control experiment was performed at the same time points and conditions but without incubation with 1 (Figure 6c ). This negative control confirmed the stability of foci over time as the intensity of the GFP-MBNL1 foci was steady (Figure 6d ). These results provide direct evidence of the ability of 1 to enter the cell and nucleus and disperse most of the MBNL1·CUG aggregates over a 2−4 h period.
Conclusion. Ligand 1 was developed based on a previously reported in vitro active ligand. 27 The in vitro activity of 1 was assessed by optical melting and surface plasmon resonance (SPR) techniques. Ligand 1 selectively binds to (CUG) 12 , stabilizes its hairpin structure, and inhibits (CUG) 12 ·MBNL1 interaction. The polyamine side-chain provides full aqueous solubility that was absent in the initially reported ligand 2. Ligand 1 penetrates the cellular as well as nuclear membrane. The bioactivity of 1 in model DM1 cells was studied by FISH technique using confocal microscopy and was found to significantly reduce the number of ribonuclear foci. In splicing experiments, 1 partially rescued the IR mis-splicing. Moreover, we studied live DM1 model cells using time-lapse confocal microscopy. For the first time, we were able to observe uptake of a small molecular inhibitor of the (CUG) 12 ·MBNL1 interaction by single live cells and further see its ability to disperse the foci over time. This approach is a powerful way to assess directly the effectiveness of small molecules targeted to CUG repeats. The positive results with compound 1 suggest that it is a good candidate for further development and therefore, toxicity and related studies are underway. The MBNL1 used here is MBNL1N containing the four zinc finger motifs of MBNL1 and a hexa His tag (C-terminus). MBNL1N is known to bind RNA with a similar affinity as the full-length MBNL1 and is commonly used in such studies. 43 All the oligonucleotides were purchased from Integrated DNA Technology and were HPLC purified. The sequences and modifications for RNA constructs used in this study are as follows:
(CUG) 12 construct for optical melting experiments: 5′−GCCU-GCUGCUGCUGCUGCUGCUGCUGCUGCUGCUGCUGGC−3′ (CUG) 12 construct for SPR experiments: 5′−GCCUGCUGCUGC-UGCUGCUGCUGCUGCUGCUGCUGCUGGC-TEG-biotin−3′ MBNL1N Protein Expression and Purification. Using BL21-CodonPlus(DE3)-RP competent cells (Stratagene), the expression of MBNL1N protein was induced with 1 mM IPTG at OD 600 0.6 in LB media with ampicillin for 2 h at 37°C. Bacterial cells were collected by centrifugation and were then resuspended in a lysis buffer containing 25 mM Tris-Cl (pH = 8), 0.5 M NaCl, 10 mM imidazole, 2 mM BME, 5% glycerol, 0.1% Triton X-100, 2 mg mL −1 lysozyme, 0.1 mM PMSF, 1 μM pepstatin, and 1 μM leupeptin and sonicated six times for 15 s each. The cell pellet was centrifuged, and the supernatant was collected and filtered through a 45 μm Millex filter. To purify MBNL1N, Ni-NTA agarose was incubated with the lysate for 1 h at 4°C and washed with a washing buffer containing 25 mM Tris-Cl (pH = 8), 0.5 M NaCl, 20 mM imidazole, and 0.1% Triton X-100, followed by elution with elution buffer of 25 mM Tris-Cl (pH = 8), 0.5 M NaCl, 250 mM imidazole, and 0.1% Triton X-100. The eluate containing the GST fusion protein was dialyzed against 1X PBS buffer for using in SPR analysis. The molecular weight was confirmed by MALDI mass spectrometry, and the concentration was determined by Bradford assay. Optical Melting Experiments. The melting temperature of the (CUG) 12 was measured on a Shimadzu UV2450 spectrophotometer equipped with a temperature controller. The path length of the cuvettes used was 1 cm. The absorbance of 3.3 μM (CUG) 12 in 1X PBS buffer in the absence and presence of 3.3 and 9.9 μM of 1 was recorded at 260 nm with a slit width of 1 nm from 10 to 95°C at a ramp rate of 0.5°C min −1 . Each profile for melting temperature analysis was generated by subtracting the absorbance of the solution of 1 in 1X PBS buffer from the (CUG) 12 /1 solution. Melting temperatures were determined by fitting the melting curve using Meltwin 3.5 software.
Surface Plasmon Resonance (SPR) Analysis. All SPR experiments were conducted on a streptavidin-coated sensor chip using a Biacore 3000 instrument. Streptavidin-coated research grade sensor chips were preconditioned with three consecutive 1-min injections of 1 M NaCl/50 mM NaOH before the immobilization was started. 3′-Biotin-labeled (CUG) 12 was captured on flow cell 2 (Response Unit, RU, between 100 and 1100). Flow cell 1 was used as a reference. Inhibition analysis was carried out in PBS 1X buffer, pH = 7.4, containing 0.05% Tween-20 and 0.2 mg mL −1 (7.4 or 580 μM nucleotides) bulk yeast t-RNA to confirm the specificity of inhibition. Various concentrations of 1 were passed over the immobilized RNA at a rate of 20 μL min −1 for 300 s. After the initial 150 s, a solution of GST-MBNL1 protein, 650 nM, in the same buffer was flowed over the surface for 150 s. The reference-subtracted sensograms were obtained by subtracting the measured RU upon injection of PBS buffer from the sensograms. After the dissociation phase, the surface was regenerated, with a pulse of 0.5% SDS and/or 100 mM NaOH, for a few times followed by a buffer wash to reestablish baseline. For inhibition studies, the resulting sensograms were set to the baseline at t = 150 s to offset the binding of 1 to the immobilized (CUG) 12 surface. The peak RU at t = 150 s was recorded and converted to the percentage of (CUG) 12 bound by MBNL1. All values were normalized to that measured in the absence of 1. The data points were fit to a four parameter logistic curve to determine the apparent IC 50 using the following equation by Kaleidagraph software:
where Y is the percentage of (CUG) 12 bound by MBNL1, Y max and Y min are the maximum and minimum of this percentage, and n is the Hill coefficient. Two or three separate SPR experiments on different sensor chips with different levels of (CUG) 12 immobilization were carried out to verify that the values are not affected by surface RNA density. FISH (Fluorescence in Situ Hybridization). A total of ca. 120,000 HeLa cells were seeded in each well of a 6-well plate on coverslips. After a day, the cells were transfected with 500 ng of DMPK−CUG 0 or DMPK−CUG 960 plasmid and 500 ng of GFP-MBNL1 plasmid using Lipofectamine following the manufacturer's protocol at cell confluence of 70−80%. 38 After 4 h, the media was changed, and 1 was added to each well at different concentrations (20, 50, 75 , and 100 μM). After 2 days, the cells were fixed with 4% PFA and then washed five times with 1X PBS. Fixed cells were permeabilized with 0.5% triton X-100 in 1X PBS at RT for 5 min. Cells were prewashed with 30% formamide in 2X SSC for 10 min at RT. Cells were probed with FISH probe (1 ng μL −1 of Cy3 CAG 10 in 30% formamide, 2X SSC, 2 μg mL −1 BSA, 66 μg mL −1 yeast tRNA) for 2 h at 37°C. Cells were then washed with 30% formamide in 2X SSC for 30 min at 37°C, followed by washing with 1X SSC for 30 min at RT. The cells were washed twice with 1X PBS, and then nuclei were stained with 1 μM To-Pro-3 and washed twice. Cells were mounted onto glass sides with ProLong Gold. Slides were imaged at RT by LSM 710, AxioObserver confocal microscopy equipment using a confocal single photon technique with a plan-Apochromat 20x/0. glucose, L-glutamine, and no antibiotics. After a day, at about 70−80% confluence, the cells were transfected with 500 ng of DMPK−CUG 0 or DMPK−CUG 960 plasmid and 500 ng of IR mini-gene plasmid using Lipofectamine 2000 and Opti-MEM reduced serum medium following the standard protocol. 38, 44 The cells were incubated at 37°C. After 4 h, the transfection medium was replaced by the DMEM medium, and the cells were treated with 1 at three different concentrations (50, 75, and 150 μM).
After 48 h, cells were harvested, and total RNA was isolated immediately using total RNA isolation kit. Then either the RNA was stored at −80°C or 1 μg of the RNA was processed with a reverse transcription step using iScript cDNA synthesis kit. The reverse transcription product was cleaned using Quick Spin kit. Approximately 70 ng of cDNA was used in PCR, 31−35 cycles (within a linear range) using PCR Master Mix kit following the standard protocol. The forward primer was 5′−GTA CCA GCT TGA ATG CTG CTC CT, and the reverse primer was 5′−CTC GAG CGT GGG CAC GCT. PCR products were separated on 8% PAGE gel in 1 X TBE, stained with EtBr in 15 min, destained with water in 15 min, and observed under Molecular Imager.
The gel image was analyzed using ImageJ and the data were plotted using Kaleidagraph. The p-values were calculated using two-tailed Student t test.
Live Cell Imaging. A total of ca. 120,000 HeLa cells were grown in an Ibidi 35 mm Petri dish with a standard bottom, high walls, and an imprinted 500 μm relocation grid. After 1 day, cell confluence reached to about 70−80%, and cells were tranfected with 500 ng of DMPK−CUG 960 plasmid and 500 ng of GFP-MBNL1 plasmid using Lipofectamine following standard protocol. After 4 h, media were changed, and cells were incubated at 37°C, 5% CO 2 . Twenty-four hours post-transfection, ligand 1 was added to final concentration of 75 μM. Live-cell, time-lapse images were taken before addition of 1 as well as at 2, 4, and 7 h time points at RT by a LSM 710, AxioObserver confocal microscopy equipment using a confocal single photon technique with a plan-Apochromat 20x/0.8 M27 objective. Image analysis was performed by Axiovision interactive measurement. For tracking the cells, DIC images were acquired simultaneously with the reflected light images using a TPMT module after setting the Koḧler illumination with a fully opened condenser aperture (0.55 NA).
